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Abstract
MAGE-C1/CT7 and MAGE-C2/CT10 are members of the large MAGE family of cancer-testis (CT) antigens. CT antigens are
promising targets for immunotherapy in cancer because their expression is restricted to cancer and germ line cells and a
proportion of cancer patients presents with immune responses against CT antigens, which clearly demonstrates their
immunogenicity. This study investigates the expression of MAGE-C1/CT7 and MAGE-C2/CT10 in primary and metastatic
melanoma. Immunohistochemical staining of tissue microarrays that consisted of 59 primary malignant melanomas of the
skin, 163 lymph node and distant melanoma metastases and 68 melanoma cell lines was performed. We found MAGE-C1/
CT7 expression in 15 out of 50 (24%) primary melanomas and 15 out of 50 (24%) cell lines, whereas MAGE-C2/CT10 was
detected in 17 out of 51 (33%) primary melanomas and 14 out of 68 (17%) cell lines. MAGE-C1/CT7 and MAGE-C2/CT10 were
both detected in 40% of melanoma metastases. Patients with MAGE-C1/CT7 or MAGE-C2/CT10 positive primary melanoma
had significantly more lymph node metastases (p=0.005 and p,0.001, resp.). Prediction of lymph node metastasis by
MAGE-C1/CT7 and MAGE-C2/CT10 was independent of tumor cell proliferation rate (Ki67 labeling index) in a multivariate
analysis (p=0.01). Our results suggest that the expression of MAGE-C1/CT7 and MAGE-C2/CT10 in primary melanoma is a
potent predictor of sentinel lymph node metastasis.
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Introduction
Melanoma is an aggressive malignant disease with poor prognosis
and its incidence is increasing faster than any other cancer. Patients
with metastatic disease have a median survival of nine months and a
five-yearsurvivalbelow 15%[1].Melanomatreatment isanongoing
issue in clinical oncology: For early stage of disease, surgical excision
remains the best treatment option whereas adjuvant therapy is not
broadly indicated due to unfavorable risk–benefit ratios [2]. In
advanced stage of disease, resistance to standard chemotherapy
frequently occurs [3,4] and standard immunotherapy shows only
moderate success [5] but recently promising data have been
shown by blockade of T cell regulatory molecules [6]. However,
spontaneous, complete regression of melanoma sporadically occurs
[7], which presumably is mediated by cancer-specific immunity
[8,9,10] and thus suggests that improvement of immunotherapeu-
tical approaches is worth pursuing. In any case, identification of
patientshavingahighriskofmelanomametastaticspreadatthetime
of diagnosis is crucial in order to detect the subset of patients most
likely to benefit from strict follow-up.
Cancer-testis (CT) antigens represent a family of proteins widely
studied in the field of cancer immunotherapy because of their
restrictive expression pattern and immunogenicity in cancer patients
[11]. In normal tissues, the expression of CT antigens is restricted to
germ line tissues (namely placenta, ovaries and testis), which express
smallamountsofHLAmolecules.Inmalignanttissues,theexpression
of CT antigens is highly erratic with frequent co-expression of several
CT antigens. Few studies demonstrated that CT antigen expression
correlates with tumor growth, survival and relapse of disease [12].
Among CT antigens, the MAGE family is one of the most extensively
investigated so far, with documented expression in several cancers.
MAGE-C1/CT7 has been simultaneously identified by representa-
tional difference analysis in a melanoma cell line [13] and its
immunogenicity assessed by serological analysis of recombinant
cDNA expression libraries (SEREX) [14] from a melanoma patient.
Subsequently, several studies showed MAGE-C1/CT7 to be highly
expressed in a variety of other human cancers [13,15]. Recently, we
demonstrated that MAGE-C1/CT7 spontaneously induces a specific
cellular immune response in melanoma patients [16], suggesting
MAGE-C1/CT7 as a potential target for melanoma immunother-
apy. However, data concerning MAGE-C1/CT7 protein expression
in melanoma are limited [15,17]. MAGE-C2/CT10 is another
M A G Ea n t i g e nw i t hh i g hs i m i l a r i t yt oM A G E - C 1 / C T 7d i s c o v e r e d
by representational difference analysis from a melanoma cell line
[18]. So far, MAGE-C2/CT10 expression in melanoma lesions has
only been analyzed by RT- PCR [18] and not on the protein level. Its
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has been shown in vivo in melanoma patients [18,19,20]. In various
tumor types, the expression of MAGE-C2/CT10 and MAGE-C1/
CT7 varied considerably [15,21]. Consequently, we investigated the
expression of MAGE-C1/CT7 and MAGE-C2/CT10 protein on
tissue microarrays comprising of 222 primary and metastatic
melanoma lesions as well as 68 melanoma cell lines by immunohis-
tochemistry.
Materials and Methods
Western blot and recombinant proteins
Recombinant MAGE-C1/CT7 and MAGE-C2/CT10 were
produced and used in western blot analysis as previously described
[22,23].
Patient’s samples and cell lines
222 melanoma lesions, including 68 primary malignant
melanoma and 163 lymph node and distant metastases of different
anatomic sites (114 brain, 24 lymph node, 7 soft tissue, 5
gastrointestinal, 4 skin, 4 lung, 2 liver, 1 parotid, 1 bone and 1
adrenal metastases) were analyzed on tissue microarrays (TMA).
Primary malignant melanomas were derived from a clinical
sentinel lymph node (SLN) trial in melanoma patients [24].
Clinical data and SLN biopsies were available for 51 of 59 primary
melanomas. Tissue of melanoma metastases was identified in the
archives of the Institute for Surgical Pathology Zurich. In addition,
cell lines derived from 68 melanoma metastases obtained from
surgical specimen of melanoma patients were analyzed. This
cohort of melanoma cell lines and melanoma metastases was
previously reported [25]. All patients were admitted at the
University Hospital of Zurich and provided written informed
consent in accordance with the Declaration of Helsinki. The
Ethical Commission Zurich, Switzerland, approved the here
reported lymph node study (approval number Stv. 16-2007).
Tissue microarray (TMA)
A morphologically representative region from paraffin-embed-
ded tissue of 68 primary melanomas and 163 melanoma
metastases was used for the construction of 4 TMAs. A core
tissue biopsy (diameter 0.6 mm) from the donor paraffin block was
used and precisely arrayed into a new recipient paraffin block
using a costumer built instrument [26]. A cell line TMA was
constructed as recently described [25].
Immunohistochemistry and immunofluorescence
4.0 mm sections were cut, mounted on glass slides, deparaffi-
nised, rehydrated and stained with hematoxylin-eosin using
standard histological techniques. For immunohistochemical stain-
ing, the Ventana Benchmark automated staining system and
Ventana reagents were used (Ventana Medical Systems, Tucson,
AZ). Immunohistochemistry and immunofluorescence were per-
formed as recently described [21,27]. Primary antibodies against
MAGE-C1/CT7 (clone CT7-33, Dako Cytomation, Dilution
1:80, Glostrup, Denmark), against MAGE-C2/CT10 (clone LX-
CT10.5, Dilution 1:100 [28] and against Ki67 (Ki67, clone MIB-
1, Dilution 1:20, Dako Cytomation, Glostrup, Denmark) were
used. Immunohistochemical labeling for MAGE-C1/CT7 and
MAGE-C2/CT10 in equal or more than 5% of melanoma cells
was recorded as positive; this cut-off has been previously reported
[15,17]. The Ki-67 Labeling Index (LI) is calculated as the
number of positive nuclei per 100 melanoma cells was recorded.
MAGE-C1/CT7-specific RT-PCR
In order to confirm the positivity of MAGE-C1/CT7 detected
by IHC and IFC RT-PCR was performed using RNA samples
extracted from melanoma cell lines which were included in the
above mentioned TMA. Melanoma cell lines were either
expressing MAGE-C1/CT7 in the cytoplasm (M01.0119), in both
nucleus and cytoplasm (M990514, M980409, M01326) or were
negative for MAGE-C1/CT7 (M950504, M010817). Cell lines
were derived from metastatic melanoma lesions and established in
the Department of Dermatology, University Hospital Zurich,
Switzerland. Total RNA was extracted by the Qiagen RNA
Extraction Kit (Qiagen, Hombrechtikon, Switzerland) and RNA
was reverse-transcribed into cDNA using the TaqMan EZ RT-
PCR kit (Applied Biosystems, Rotkreuz, Switzerland) according to
the manufacturer’s instructions. For PCR, cDNA was diluted in
TaqMan universal PCR master mix supplemented with a MAGE-
C1/CT7-specific TaqMan probe and MAGE-C1/CT7-specific
forward (59-GACGAGGATCGTCTCAGGTCAGC-39) and re-
verse (59-ACATCCTCACCCTCAGGAGGG-39) primers (all
from Applied Biosystems, Rotkreuz, Switzerland).
Statistical analysis
Categorical data were compared between groups using chi-
square test or Fisher’s exact test where appropriate. Continuous
data were compared using the Mann-Whitney test. A logistic
regression was performed to evaluate the predictive power of Ki-
67 LI and MAGE-C1/CT7 expression in primary malignant
melanoma for lymph node metastasis. Statistical analyses were
performed using SPSS 13.0 (SPSS Inc, Chicago IL). Multivariable
exact logistic regression was performed using Stata 10.0 (Stata-
Corp, Lakeway Drive, TX) to analyze predictive power of
positive MAGE-C1/CT7 or MAGE-C2/CT10 adjusted for Ki-67
proliferation rate (Ki-67 LI). p-values ,0.05 were considered
significant.
Results
MAGE-C1/CT7 and MAGE-C2/CT10 expression
Antibodies specific for MAGE-C1/CT7 and MAGE-C2/CT10
were confirmed on WB with recombinant proteins (Fig. S1). MAGE-
C1/CT7 was found in the nucleus or cytoplasm of melanoma cells.
Most cases showed a combined nuclear and cytoplasmatic (n=10) or
only a cytoplasmatic (n=4) MAGE-C1/CT7 expression (Fig. 1A, B
or C). The MAGE-C1/CT7 expression pattern was further analyzed
by immunofluorescence staining for MAGE-C1/CT7 and for a
nuclear marker (DAPI). Only one primary melanoma and one
melanoma cell line were characterized by an exclusive nuclear
MAGE-C1/CT7 expression. RT-PCR confirmed MAGE-C1/CT7
expression in all cell lines, independently of the sub-cellular
expression pattern and we therefore scored both expression patterns
as positive(Fig. 2). We observed MAGE-C1/CT7 expression in 15 of
50 cell lines (24.2%), 12 of 59 primary melanomas (20.3%), and 66 of
163 metastases (40.5%) in the TMAs (Table 1).
In contrast to MAGE-C1, MAGE-C2/CT10 expression was
only found in the nucleus (Fig. 3). MAGE-C2/CT10 expression
was identified in 14 of 68 cell lines (20%), in 17 of 51 primary
melanomas (33%), and in 62 of 155 metastases (40%) (Table 2).
Due to technical reasons, biopsies from 8 primary lesions and 8
metastases from the original TMA could not be analyzed for
MAGE-C2/CT10. The expression of these two antigens signifi-
cantly correlated with each other (p,0.001). Co-expression was
detected in 9 out of the total 51 (18%) primary lesions and 36 out
of total 137 (26%) metastases.
CT7 and CT10 Predict Melanoma Metastasis
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The availability of primary melanoma from a SLN study [24]
allowed us to directly analyze the relevance of MAGE-C1/CT7
and MAGE-C2/CT10 expression for lymph node metastasis.
MAGE-C1/CT7 positive primary melanomas had significantly
more frequent SLN lymph node involvement (pN1) than negative
ones (44% vs. 3%; p=0.001; Table 3A) with a positive predictive
value of 87%. Similarly, MAGE-C2/CT10 positive primary
melanomas showed significantly more lymph node involvement
(pN1) than negative melanomas (58% vs. 8%; p=0.001; Table 3B)
with a positive predictive value of 80%.
We described in a previous study that the tumor cell proliferation
rate as measured by the Ki-67 Labeling Index significantly correlates
with the presence of lymph node metastases (p=0.03) in univariate
analysis [24] (Table 4A). A multivariable exact logistic regression
analysis revealed that MAGE-C1/CT7 as well as MAGE-C2/CT10
expression in the primary lesions are independent predictors of
metastases when adjusted for Ki-67 (p=0.005 and p,0.01 resp.),
whereas Ki-67 is not an independent predictor (p=0.29; Tab. 4A
and p=0.3 Tab. 4B resp.). Both MAGE-C1/CT7 and MAGE-C2/
CT10 remain independent predictors when analyzed together by a
multivariate analysis even if adjusted for each other (p=0.03 und
p=0.01 resp.) (Table 4C). Univariate survival analysis of 51 patients,
for whom follow-up information was available, revealed that MAGE-
C1/CT7 and MAGE-C2/CT10 expression did not correlate with
overall survival.
Discussion
In this study we demonstrate the expression of MAGE-C1/CT7
and MAGE-C2/CT10 protein in primary melanoma and an
increased expression in melanoma metastases. Furthermore, the
expression of MAGE-C1/CT7 and/or MAGE-C2/CT10 in
primary melanoma indicates a high risk of lymph node metastasis,
which is of great clinical relevance as it identifies patients that
require a strict follow-up.
MAGE-C1/CT7 and MAGE-C2/CT10 were co-expressed in
more than 40% of melanoma lesions that were expressing either
one of these two antigens. This observation is in accordance to
other studies showing frequent co-expression of these and other
CT antigens, justifying polyvalent CT-vaccine strategies in several
tumor types [29]. MAGE-C1/CT7 was found in the nucleus as
well as in the cytoplasm, while MAGE-C2/CT10 was present
exclusively in the nucleus. This differential expression pattern is
remarkable as these two antigens share a highly similar sequence
Figure 1. MAGE-C1/CT7 protein expression pattern in melanoma. MAGE-C1/CT7 expression was analyzed by immunohistochemistry on
melanoma lesions at two different magnifications (5x, 20x) (left and middle panels) and by immunofluorescence on cell lines (100x) (right panels).
Expression of MAGE-C1/CT7 is shown only in the nucleus (A), only in the cytoplasm (B) and both in nucleus and cytoplasm (C).
doi:10.1371/journal.pone.0021418.g001
Figure 2. MAGE-C1/CT7 RNA expression in cell lines. MAGE-C1/
CT7 RNA expression was analysed on the following cell lines: (a)
M950504, (b) M980409, (c) M010119, (d) M990514, (e) M01817 and (f)
M010326 melanoma cell lines; (a) and (e) did not express MAGE-C1/CT7;
(b), (c), (d) and (f) were positive. Beta actin control is shown.
doi:10.1371/journal.pone.0021418.g002
Table 1. MAGE-C1/CT7 protein expression in melanoma
biopsies from primary, metastatic lesions and melanoma cell
lines.
CT7 Positive
N N (%)
Cell lines 50 15 (24)
Primary melanoma 59 12 (20)
Metastases 163 66 (40)
MAGE-C1/CT7 expression was evaluated using tissue microarrays (TMAs)
consisting of 50 melanoma cell lines, 59 primary melanoma lesions and 163
metastases. Expression was considered positive if at least 5% of the tumor cells
expressed MAGE-C1/CT7.
doi:10.1371/journal.pone.0021418.t001
CT7 and CT10 Predict Melanoma Metastasis
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(melanoma antigen encoding gene) homologous sequence.
MAGE-C1/CT7 has a unique feature in a form of repetitive
sequence in the N-terminal region with an almost invariable core
of 10 almost-exact repeats of 35 amino acid residues. Proteins with
similar structure were shown to be involved in many physiological
processes, such as cell cycle control, transcriptional regulation, cell
signaling and apoptosis [30]. We recently investigated expression
of MAGE-C1/CT7 in myeloma plasma cells from bone-marrow
lesions of multiple myeloma patients and described that the sub-
cellular localization of MAGE-C1/CT7 (nucleus or cytoplasm) has
prognostic value such that combined nuclear and cytoplasmic
expression correlates with reduced survival [27]. We could not
confirm this correlation in melanoma due to the low number of
lesions with an exclusive MAGE-C1/CT7 nuclear expression.
Furthermore, a possible role of MAGE-C1/CT7 in promoting
survival of myeloma cells through reduced apoptosis has been
recently described [31]. Along the same line, we observed that
MAGE-C1/CT7 and MAGE-C2/CT10 are more frequently
expressed in melanoma metastases than in primary melanoma
(20% versus 40%). This result is compatible with previous studies
and supports a possible role for CT antigens in tumor progression
[27,32,33,34,35] although these observations are difficult to
confirm since the exact function of these antigens remains largely
unknown. Further investigation of MAGE antigen function in
these lesions might indeed provide fruitful insights in melanoma
tumour biology.
We demonstrate that MAGE-C1/CT7 and MAGE-C2/CT10
expression in primary melanoma is a faithful predictor of lymph
node metastasis in a patient cohort included in a recent study
performed on tissue coming from sentinel lymph node biopsies
from melanoma patients [24]. The SLN procedure is a technique
in which, after tumor excision, the sentinel lymph node is removed
and examined to determine whether malignant cells are present.
This procedure has been successfully validated for melanoma as a
mean of metastasis detection in patients with intermediate-
thickness lesions [36]. Present state of the art of melanoma
diagnosis includes Ki-67 staining as a prognostic marker
[37,38,39,40]. However, prediction of lymph node (LN) metastasis
based on MAGE-C1/CT7 and MAGE-C2/CT10 expression in
primary melanoma is independent of Ki-67 expression. Moreover,
Ki-67 is not an independent predictive factor for metastatic spread
if adjusted for MAGE-C1/CT7 or MAGE-C2/CT10, suggesting
that these two CT antigens are superior markers to indicate lymph
node metastasis. Our findings may have an important clinical
impact because predictive markers of LN involvement are
required for a better preoperative planning of the SLN procedure.
Expression of MAGE-C1/CT7 and MAGE-C2/CT10 in
melanoma tissues was not correlated with overall patient survival
which seems to be in contrast with the here reported results
indicating a potential role in the tumorigenic process. This
discrepancy might be due to the spontaneous immune response
targeting these antigens which can block or down-regulate the
tumor growth, as was previously shown for melanoma and several
other cancers [41,42]. Immunogenicity of MAGE-C2/CT10 has
been previously demonstrated in melanoma and leukemia patients
consisting of both cellular and humoral immune responses
[18,19,20,43,44]. We recently showed spontaneous MAGE-C1/
CT7-specific CD4
+ T cells in the blood of patients with melanoma
[16] and MAGE-C1/CT7-specific humoral response in multiple
myeloma patients [23]. This immunogenicity taken together with
frequent expression showed above strongly suggests that MAGE-
C1/CT7 and MAGE-C2/CT10 are potential candidates for
cancer immunotherapy in a large group of melanoma patients.
Figure 3. MAGE-C2/CT10 protein expression in melanoma.
MAGE-C2/CT10 nuclear expression analyzed by immunohistochemistry
from a metastatic melanoma lesion (20X).
doi:10.1371/journal.pone.0021418.g003
Table 2. MAGE-C2/CT10 protein expression in melanoma
biopsies from primary, metastatic lesions and melanoma cell
lines.
CT10 Positive
N N (%)
Cell lines 68 14 (20)
Primary melanoma 51 17 (33)
Metastases 155 62 (40)
MAGE-C2/CT10 expression was evaluated using tissue microarrays (TMAs)
consisting of 68 melanoma cell lines, 51 primary melanoma lesions and 155
metastases. Expression was considered positive if at least 5% of the tumor cells
expressed MAGE-C2/CT10.
doi:10.1371/journal.pone.0021418.t002
Table 3. Correlation between MAGE-C1/CT7 (A) and MAGE-
C2/CT10 (B) expression in primary melanoma and lymph node
metastases.
A
pN Stage N CT7 Positive N(%) p value
pN1 16 7 (44) 0.001
pN0 35 1 (3)
B
pN Stage N CT7 Positive N(%) p value
pN1 17 10 (58) ,0.001
pN0 34 3 (8)
Primary melanoma with sentinel lymph node (SLN) involvement (pN1) and
primary melanoma without SLN involvement (pN0). The correlation was
considered significant by a p-value #0.05.
doi:10.1371/journal.pone.0021418.t003
CT7 and CT10 Predict Melanoma Metastasis
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MAGE-C1/CT7 in a large proportion of melanoma patients, who
could thus benefit from a specific anti-tumor immune response
following vaccination with these antigens. Furthermore, our results
identify the expression of MAGE-C1/CT7 and MAGE-C2/CT10
in the primary melanoma lesion as strong prediction markers for
SLN metastases in melanoma patients; we therefore propose
inclusion of these markers, together with Ki-67, to improve
melanoma work-up.
Supporting Information
Figure S1 Antibody specificity by Western Blot. Recom-
binant proteins (a) recombinant MAGE-C2/CT10 and (b) recombi-
nant MAGE-C1/CT7) were detected by the corresponding monoclo-
nal antibodies: anti-MAGE-C2/CT10 (A) and MAGE-C1/CT7-
specific antibody (B). Degradation products can be seen in both cases.
(TIF)
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